Khng cn phi s dng nhiu vin ung
293 (1), F30-40 (2007)
4.1.2 Autism Spectrum disorders Surprisingly, there are few studies looking at sulforaphanes effectiveness in autism preclinical models considering most of the clinical trials (discussed later) for sulforaphane in neurological conditions focused on the ASD patient pool
Peng, F, Sinjab, A, Dai, Y, Treekitkarnmongkol, W, Yang, S, Gomez Bolanos, L, Zhou, T, Chen, M, Serrano, A, Krishna, A, Karimi, N, Sharma, M, Basi, A, Pei, G, Liao, J, Liu, Y, Feng, J, Rahal, Z, Liu, Y, Jiang, J, Yu, K, Noun, T, Liu, Y, Khan, KB, Cho, KS, Chen, J, Solis Soto, LM, Mazzilli, SA, Dubinett, SM, Cascone, T, Spira, A, Swisher, SG , Jimbo, N, Hayashi, T, Kishikawa, S, Takamochi, K, Itoh, T, Yao, T, Suzuki, K, Kalhor, N, Wistuba, II, Li, M, Moghaddam, SM, Fujimoto, J, Burks, JK, Myers, JN, Akdemir, KC, Wang, L, Kadara, HN
Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion, slows gastric emptying, and suppresses appetite through the GLP-1 receptor
